Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus lidocaine versus saline for extubation and hemodynamic control in kidney transplantation
IRCT20231113060037N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of dexmedetomidine and lidocaine in end-stage kidney disease (ESKD) (3 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Quality of extubation, Hemodynamic stability and 1 more. Started Jun 2026; status: completed.
02
Drugs
dexmedetomidinelidocaine
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT20231113060037N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231113060037N2.